ORTEXORTEX News
Tracking VST? Get live short interest, options flow, and signals on ORTEX.Sign up free →
VS
Trader NoteVST

VST drops 7% in a week while the CEO quietly bought the dip

By ORTEX News · Edited by , Editor, ORTEX NewsUpdated 3 min readdata as of 21 Oct 2026, 20:16

Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish

ShareXLinkedInReddit

Vistra Corp. fell 7.4% over the past week to close at $150.32, a sharper move than its closest peer TLN, which lost 8.6%, while the broader group of independent power producers shed a median 3%. The week's most actionable fact sits in the insider register: CEO James Burke spent roughly $1.17 million buying shares on the open market in late August, at prices around $135, a discretionary purchase with no 10b5-1 plan attached.

That distinction matters. Every other insider transaction in the past 90 days was a pre-scheduled plan sale. The CFO, Kristopher Moldovan, sold 20,000 shares in early October at $165 under a 10b5-1 arrangement. The EVP of Vistra Retail, Scott Hudson, sold a combined 58,000 shares across September under the same structure. Both are compensation-mechanics moves, not conviction signals. Burke's cluster of open-market purchases in August, averaging around $135.40 a share, is a different category of information. The net 90-day insider position works out to roughly minus $15.5 million in value sold, but strip out the plan sales and the CEO's discretionary buying is the signal worth isolating. The stock has since moved from those $135 levels back toward $150, so the trade is modestly in the money.

Short positioning does not add much urgency to the story. Short interest is running at 3.1% of the free float, up about 1.7% on the week but still near the lower end of where it has traded over the past several weeks. Borrow availability is extraordinarily loose at over 5,000%, meaning there are more than 50 shares available to lend for every one already borrowed. Cost to borrow is just 0.47%, up roughly 35% on the week but still firmly in sub-1% territory. None of the lending-market readings suggest any squeeze dynamic or unusual pressure to cover. Options positioning is mildly defensive, with the put/call ratio at 1.12 against a 20-day average of 1.08, a little above normal but far below the 52-week high of 1.72. The overall configuration looks like routine caution, not a directional bet.

Analysts are broadly constructive but have been trimming numbers. Morgan Stanley's Stephen Byrd, who covers Vistra as Overweight, nudged his price target down by $1 to $226 this week, the second time he has touched it since raising to $227 in August. BMO Capital lowered its target more meaningfully, from $231 to $210, while maintaining Outperform. CIBC initiated coverage at Outperformer with a $201 target last week. The mean analyst target across the group is $209.76, implying roughly 40% upside from the current price, though it is worth noting the spread of targets is wide. The Street's analyst recommendation differential ranks in the 97th percentile of Vistra's universe, reflecting unusually strong consensus bullishness. The bull case centres on free cash flow conversion targets of 60% or above from 2026 and the addition of Cogentrix generation capacity. The bear case points to the stock's roughly 30% pullback from its peak and continued margin risk from commodity price volatility. Valuation sits at around 15 times trailing earnings and 9.3 times EV/EBITDA, both modestly higher over the past month.

The EPA's Clean Air Markets Program data shows Vistra's gross capacity factor by operator came in at 51.75% in June 2026, the smallest June reading on record since 2024. That dataset carries no measured lead against Vistra's reported figures, so it is colour rather than a directional indicator for the November 5 print. What it does confirm is that summer generation efficiency was under pressure, a fact the bear case has already priced into margin estimates. Separately, Wikipedia page-view data registered an elevated retail attention z-score of 2.54 as of late September, well above the stock's own recent history, though that signal too has no measured lead against reported revenue or earnings.

The next hard date is November 5, when Vistra reports Q3 results. With the stock 7.4% lower on the week and trading at a 28% discount to the mean analyst target, the gap between where the Street is anchored and where the market has pushed the price is the specific thing to watch into that date.

Stocks in this article

See the live data behind this article on ORTEX.

Open VST on ORTEX →

How this article was generated

Generated
21 Oct 2026, 20:17
Data as of
21 Oct 2026, 20:16
Prompt version
v1.0
Data sources
Short interestCost to borrowUtilizationOptions flowEarningsAnalyst consensusInstitutional positioningORTEX Alpha signalsRecent ORTEX notesAlt Data

ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.